Nivolumab confirmed its significant superiority to dacarbazine in previously untreated metastatic MM patients without BRAF mutation: at 12 months, the overall survival was 73% in the nivolumab arm vs. 42% in the dacarbazine arm (p < 0.001) [53]. This evidence concerns the gene BRAF and Miyoshi myopathy.